News & Updates
Showing Pharmacy articles
Showing
Dolutegravir knocks down HIV faster than bictegravir in French study
Final analysis of the BicDol study, presented at AIDS 2026, suggests that a first-line triple antiretroviral regimen containing dolutegravir suppresses HIV more rapidly than one containing bictegravir, particularly among patients with the highest viral loads.
Antibiotic use ups risk of IBD flare-ups
Use of antibiotics for nongastrointestinal (non-GI) infections results in a three- to fivefold increase in the risk of inflammatory bowel disease (IBD) flare-ups, a study has found. The risk gradually declines and returns to baseline level about 6 weeks after exposure.
Fewer major bleeds with prasugrel as default antiplatelet after PCI
When prasugrel is the default antiplatelet for patients with acute coronary syndromes (ACS) undergoing PCI*, fewer major bleeds occur than when ticagrelor is the default, according to the SWITCH-SWEDEHEART study presented at ESC 2026. This benefit is not accompanied by increased ischaemic events.
Early PCSK9 inhibition post-MI lowers LDL-C: Does it influence clinical outcomes?
Initiating the PCSK9* inhibitor evolocumab in the cath lab prior to PCI** in patients with acute myocardial infarction (MI) dramatically lowers LDL-C compared with standard care in the phase IV AMUNDSEN trial presented at ESC 2026.